Immunosuppression is a common reason for drug withdrawal from the market. The traditional immune function test used to estimate materials’ immunosuppression is T cell dependent antibody response (TDAR). This method involves a 28 day, in vivo, study evaluating animal antibody titers to a known antigen (KLH) with and without challenge. Due to the limited quantities of novel drug candidates, an in vitro method called Human Leukocyte activation (HuLa) has been developed as a substitute to the traditional TDAR assay in early preclinical development. The method presented herein is based on the HuLa assay originally developed by Mark Collinge et al at Pfizer (1). The protocol presented in this document has been adapted for use with engineered nanomaterials.

• NCL_Method_ITA-18_June2020.pdf(PDF | 429 KB)

Researchers should cite this work as follows:

• Timothy Potter, Edward Cedrone, Barry Neun, Marina Dobrovolskaia (2020). NCL Method ITA-18. (Version 2.0). NCI Hub. doi:10.17917/3429-7641

  BibTex | EndNote

1. leukocyte proliferation
2. Nanoparticles